STOCK TITAN
  1. Home
  2. News
  3. ILMN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated news page for Illumina (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Illumina's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Illumina's position in the market.

News
Illumina Ventures Labs Launches in the US and the UK to Enable More Rapid Value-Creation for Start-Ups Advancing Human Health
Rhea-AI Summary
Illumina Ventures Labs (IVL) is now operational and finalizing agreements with several startup companies. IVL is part of Illumina Ventures, supporting early-stage genomics startups. IVL provides fully equipped genomics labs, mentorship, and connections to other companies within the Illumina Ventures portfolio. Companies can stay in Labs for up to eighteen months and employ virtual and hybrid formats. After leaving the Labs, companies will be de-risked and attractive investment opportunities for the wider venture capital community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
News
BeniComp to Offer GRAIL’s Multi-Cancer Early Detection Test for Employee Health Screening
Rhea-AI Summary
GRAIL, LLC (ticker symbol: GRL) and BeniComp partner to make Galleri® multi-cancer early detection (MCED) screening test available to eligible patients through BeniComp Select members. This partnership aims to enhance proactive and preventive health management, offering better access to care and equipping participants with proactive cancer screening tools. The Galleri® test, introduced in 2021, utilizes next-generation sequencing and machine learning to detect a signal shared by many cancers, including those without recommended screenings. The collaboration between GRAIL and BeniComp signifies a step forward in early cancer detection and preventive health measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
News
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
Rhea-AI Summary
Illumina, Inc. (Nasdaq: ILMN) announces unaudited preliminary financial results for Q4 2023 and fiscal year 2023, with consolidated revenue of approximately $1,115 million for Q4 2023, up 3% from Q4 2022, and approximately $4,497 million for fiscal year 2023, down 2% from fiscal year 2022. Core Illumina revenue was approximately $1,090 million for Q4 2023, up 2% from Q4 2022, and approximately $4,431 million for fiscal year 2023, down 3% from fiscal year 2022. The company also shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
earnings
News
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Rhea-AI Summary
Illumina Inc. (NASDAQ: ILMN) signs collaboration agreement with Janssen Research & Development, LLC for the development of a novel molecular residual disease assay using whole-genome sequencing for oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
-
News
Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
Rhea-AI Summary
Illumina, Inc. (ILMN) to Release Q4 and Full Year 2023 Results on February 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
earnings
-
News
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
Rhea-AI Summary
Illumina Inc. (NASDAQ: ILMN) delivered approximately 86,000 whole genomes in 2023, including a unique diverse ancestry cohort. The company announced three new members of the Alliance for Genomic Discovery (AGD), including Bristol Myers Squibb (BMS), GSK, and Novo Nordisk, who will co-fund the whole-genome sequencing of 250,000 DNA samples. This collaboration aims to generate and analyze more genomic, multimodal phenotypic, and multiomic data to improve human health and drug discovery. AGD completed whole-genome sequencing of approximately 86,000 DNA samples, including a diverse ancestry cohort of 35,000 individuals primarily of African ancestry. The alliance is applying innovative, large-scale analysis tools to the DNA data to identify disease associations and drug targets for intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
News
Madryn Asset Management Reiterates Alternative Path to SomaLogic’s Value-Destructive Proposed Merger with Standard BioTools
Rhea-AI Summary
Madryn Asset Management, LP (Madryn) reiterates its view that there is a viable alternative to the proposed merger between SomaLogic, Inc. (SLGC) and Standard BioTools Inc. (LAB). They believe that SomaLogic's cash position and near-term commercial opportunities mitigate the need for the merger, and they urge shareholders to vote against it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Nucleus Genomics Wants To Make Personalized Health Care a Reality
Rhea-AI Summary
Nucleus Genomics (NUCL) is partnering with Illumina to scale their vision of leveraging whole-genome sequencing (WGS) to build a more proactive health care system. The company aims to make WGS widely available to the public and is set to launch in the US in 2024. Nucleus has received $18 million in funding and is focused on combining over 70,000 genetic tests into one comprehensive product, including polygenic risk scores (PRS) and nongenetic information for a more complete risk assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
-
News
Illumina To Webcast Upcoming Investor Conference
Rhea-AI Summary
Illumina, Inc. (NASDAQ: ILMN) executives to speak at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. Webcast and Q&A session to be available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
News
A Lesser-Known Application of Genomics: Reducing Cow Burp Intensity
Rhea-AI Summary
DataGene (Ticker: DG) introduces Sustainability Index for dairy cattle herds to combat methane emissions, a significant driver of global warming. The index aims to address the environmental impact of cattle farming by focusing on the genetic factors influencing methane emissions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.08%
Tags
none
Stock ILMN logo
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

#529 Ranked by Market Cap
#4729 Ranked by Stock Gains
N/A Ranked by Dividends

ILMN Stock Data

20.24B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
San Diego

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.